Juvenile respiratory papillomatosis: acyclovir reassessed.
Four patients with aggressive respiratory papillomatosis have been treated with oral Acyclovir as adjuvant therapy while continuing to undergo regular endoscopy and laser treatment to the lesions. The duration of Acyclovir administration ranged from 2 weeks to 3 months. Two patients had papillomatosis confined to the larynx and two in addition had disease in the lower respiratory tract. One of the four patients had less aggressive disease during the treatment period. Acyclovir does not appear to significantly influence respiratory papillomatosis. Acyclovir's activity is dependent upon the presence of virally encoded thymidine kinase. This enzyme is not known to be encoded by papilloma viruses. Acyclovir is not recommended in the treatment of juvenile respiratory papillomatosis.
Morrison
G A
GA
Department of Otolaryngology, Hospitals for Sick Children, London, UK.
Evans
J N
JN
D000212:Acyclovir / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy*; D010212:Papilloma / Q000188:drug therapy*; D012142:Respiratory Tract Neoplasms / Q000188:drug therapy*
D000212:Acyclovir